SPRINT — Sprint Bioscience AB Income Statement
0.000.00%
Last trade - 00:00- SEK166.71m
- SEK155.77m
- SEK65.64m
Annual income statement for Sprint Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 16.9 | 35.1 | 0.083 | 50.5 | 65.6 |
| Cost of Revenue | |||||
| Gross Profit | 6.43 | 24.7 | -12.8 | 41.8 | 37.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 54.7 | 60.7 | 60.8 | 51.3 | 85.3 |
| Operating Profit | -37.8 | -25.6 | -60.7 | -0.845 | -19.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.8 | -25.1 | -60.2 | -0.438 | -18.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -42.8 | -25.1 | -60.2 | -0.438 | -18.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -42.8 | -25.1 | -60.2 | -0.438 | -18.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.8 | -25.1 | -60.2 | -0.438 | -18.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.03 | -0.712 | -1.41 | -0.006 | -0.257 |
| Dividends per Share |